This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Collins, S Articles by Groudine, M Search for Related Content PubMed PubMed Citation Articles by Collins, S Articles by Groudine, M

Expression of bcr and bcr-abl fusion transcripts in normal and leukemic cells.

Molecular Medicine Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98104.

ABSTRACT

The translocation of the c-abl oncogene from chromosome 9 to the bcr gene on chromosome 22 in cases of Philadelphia chromosome-positive chronic myelogenous leukemia (CML) generates an aberrant bcr-abl fusion transcript which may be intimately related to the pathogenesis of CML. Because factors controlling normal bcr expression might also be involved in the expression of this aberrant bcr-abl transcript, we studied the patterns of expression of the normal bcr gene in different cell types. We found that the normal bcr gene was expressed in many different types of human cells. Moreover, the bcr gene was evolutionarily conserved, and homologous bcr genomic sequences and RNA transcripts were readily detected in chick tissue. The highest level of bcr expression in chick tissue was in brain tissue, the lowest level was in liver tissue, and a truncated bcr mRNA was noted in chick testes. Normal bcr transcripts, in addition to the aberrant bcr-abl hybrid transcripts, have been found in all Philadelphia chromosome-positive CML cells studied to date. Within a given CML sample, the relative amounts of normal bcr RNA and aberrant bcr-abl RNA were similar. In addition, the normal bcr and the aberrant bcr-abl hybrid transcripts demonstrated similarly prolonged half-lives compared with that of the normal abl-related transcripts in CML cells. These findings suggest that in CML cells, similar cellular mechanisms control the steady-state levels of both the normal bcr and the bcr-abl fusion RNAs.

This article has been cited by other articles:

• Hughes, T., Deininger, M., Hochhaus, A., Branford, S., Radich, J., Kaeda, J., Baccarani, M., Cortes, J., Cross, N. C. P., Druker, B. J., Gabert, J., Grimwade, D., Hehlmann, R., Kamel-Reid, S., Lipton, J. H., Longtine, J., Martinelli, G., Saglio, G., Soverini, S., Stock, W., Goldman, J. M. (2006). Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 108: 28-37 [Abstract] [Full Text]  
• Johnson, B. S., Mueller, L., Si, J., Collins, S. J. (2002). The cytokines IL-3 and GM-CSF regulate the transcriptional activity of retinoic acid receptors in different in vitro models of myeloid differentiation. Blood 99: 746-753 [Abstract] [Full Text]  
• Laurent, E., Talpaz, M., Kantarjian, H., Kurzrock, R. (2001). The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis. Cancer Res. 61: 2343-2355 [Full Text]  
• Papadopoulos, K. P., Suciu-Foca, N., Hesdorffer, C. S., Tugulea, S., Maffei, A., Harris, P. E. (1997). Naturally Processed Tissue- and Differentiation Stage-Specific Autologous Peptides Bound by HLA Class I and II Molecules of Chronic Myeloid Leukemia Blasts. Blood 90: 4938-4946 [Abstract] [Full Text]  
• Haataja, L., Groffen, J., Heisterkamp, N. (1997). Characterization of RAC3, a Novel Member of the Rho Family. J. Biol. Chem. 272: 20384-20388 [Abstract] [Full Text]  
• Tsai, S, Bartelmez, S, Heyman, R, Damm, K, Evans, R, Collins, S J (1992). A mutated retinoic acid receptor-alpha exhibiting dominant-negative activity alters the lineage development of a multipotent hematopoietic cell line.. Genes Dev. 6: 2258-2269 [Abstract]